glennl schreef:Heel wat shorters... Short selling is niet meer toegelaten sinds 20u13 tem 23/1 02u.

jpke schreef:- 8.53 % ..Morgen beter

insider schreef:

glennl schreef:Heel wat shorters... Short selling is niet meer toegelaten sinds 20u13 tem 23/1 02u.

hoe bedoel je Glenn ... sorry maar ik volg niet ...

insider schreef:ok nu begrijp ik u beter. is dat alleen voor DPRX zo ?

Results from the phase 3 clinical studies on Locilex are expected to be announced in mid-2015 and Haynor and Dipexium officials are optimistic that the results will be positive and encouraging. Dipexium’s stock is currently trading at $11 a share after hitting a high of $15.86 last year. Haynor has a 12-month price target of $21.75, based on the company’s projected revenues and Locilex’s potential value on other possible uses.

Ben C. Haynor, analyst at securities firm Feltl & Co., who rates Dipexium as a strong buy, says the company’s product Locilex, currently in phase 3 clinical trials, could meet clinical guidelines as a treatment for diabetic foot infections. There isn’t any approved drug for such foot diseases, and drugs that are currently recommended for such ailments, notes Haynor, that are currently being used are off-label and carry a host of risks, such as antibiotic resistance, narrow spectrums, poor safety profile, and drug interactions.